Intellipharmaceutics International Inc. (IPCI)

[fabius]

Samsa,

"when it went standard"

Rexista didn't went standard, p3 studies were allowed to be jumped, confirmed by the 25th sept FDA decision. HAP/HAL studies being another story.

The question here (which will remain unresolved) to me is: WHEN (at which stage) Podras was planned to be added to Rexista ? Likely after FDA approval.
But now timeline changed; Rexista is not going to be approved before anytime soon, therefore the point Angelo is making looks interesting to me: chosing to add Podras to an "alternate" oxydone signals the will to advance Podras studies, being the alternative to add-it to a still to approved drug.
Therefore, Always aware that the worst usually happens when Odidi is the decision maker, this time there could be some positive.

JMHO